|
|
Sunshine Biopharma Inc (NASDAQ: SBFM) |
|
Price: $1.4400
$-0.04 
-2.373%
|
| Day's High:
| $1.5
| Week Perf:
| -9.43 %
|
| Day's Low: |
$ 1.44 |
30 Day Perf: |
-3.36 % |
| Volume (M): |
43 |
52 Wk High: |
$ 3.90 |
| Volume (M$): |
$ 61 |
52 Wk Avg: |
$2.14 |
| Open: |
$1.44 |
52 Wk Low: |
$0.15 |
|
|
| Market Capitalization (Millions $) |
4 |
| Shares
Outstanding (Millions) |
3 |
| Employees |
17 |
| Revenues (TTM) (Millions $) |
36 |
| Net Income (TTM) (Millions $) |
-5 |
| Cash Flow (TTM) (Millions $) |
-9 |
| Capital Exp. (TTM) (Millions $) |
2 |
Sunshine Biopharma Inc
Sunshine Biopharma Inc is a pharmaceutical research and development company based in Canada. The company focuses on developing treatments for various forms of cancer, including pancreatic cancer and breast cancer. Their flagship product is Adva-27a, a chemotherapy drug being developed for pancreatic cancer treatment.
Sunshine Biopharma Inc utilizes a unique approach to drug development by leveraging their proprietary research platform, which combines computer modeling with traditional laboratory techniques. This approach allows them to identify and target specific molecular targets that are crucial for cancer cell survival.
The company's goal is to develop innovative and more effective treatments for cancer patients, with a focus on improving patient outcomes and quality of life. They aim to bring their drug candidates through the necessary stages of preclinical and clinical trials in order to obtain regulatory approval and make them available to patients in need.
Overall, Sunshine Biopharma Inc is dedicated to advancing the field of cancer research and providing hope to patients by developing novel therapies that could potentially make a significant impact in the fight against cancer.
Company Address: 333 Las Olas Way Fort Lauderdale 33301 FL
Company Phone Number: 330-0684 Stock Exchange / Ticker: NASDAQ SBFM
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Sunshine Biopharma Inc
Sunshine Biopharma Inc, a pharmaceutical company specializing in life-saving medicines, recently announced its relocation to New York City, positioning itself at the heart of the global pharmaceutical industry. The company's new headquarters is located at 1177 Avenue of the Americas, 5th Floor, New York, NY 10036, while its satellite office in Montreal, Canada will continue to operate.
This strategic move is aimed at enhancing Sunshine Biopharma's growth prospects and taking advantage of the robust healthcare infrastructure, world-class talent pool, and extensive industry network present in New York City. By being in close proximity to key players in the pharmaceutical sector, the company hopes to further expand its presence in the United States, a crucial market for pharmaceutical advancements.
|
| Sunshine Biopharma Inc
Sunshine Biopharma Inc, a leading pharmaceutical company specializing in life-saving medicines, recently made a significant announcement that it has relocated its headquarters to New York City. The company's new office, located at 1177 Avenue of the Americas, 5th Floor, New York, NY 10036, aims to position Sunshine Biopharma at the center of the global pharmaceutical industry and enhance its growth prospects.
With a specific focus on therapeutic areas such as oncology and antivirals, Sunshine Biopharma has been at the forefront of groundbreaking research and innovation. By shifting its principal office to New York City, the company aims to leverage the city's robust healthcare infrastructure, world-class talent pool, and extensive industry network. This strategic move reflects Sunshine Biopharma's commitment to further expanding its presence in the United States, which is a key market for pharmaceutical advancements.
|
| Product Service News
Published Mon, Dec 4 2023 1:30 PM UTC
Sunshine Biopharma Expands Presence in New York City and Shows Impressive Revenue Growth
In a recent announcement, Sunshine Biopharma, Inc. (NASDAQ: SBFM), a renowned pharmaceutical company specializing in life-saving medicines, revealed that it has relocated its headquarters to New York City. The company s new office is situated at 1177 Avenue of the Americas, 5th Floor...
|
| Sunshine Biopharma Inc
Sunshine Biopharma Inc: A Bullish Outlook for Profitability and Growth
In a remarkable turn of events, Sunshine Biopharma Inc has experienced an astonishing revenue elevation of 4385.926% year on year, reaching an impressive $5.96 million in its September 30, 2023 report. What makes this achievement even more extraordinary is the fact that the company's bottom-line has turned positive, with a net profit of $0.04. This outcome has left many industry experts astounded and has positioned Sunshine Biopharma Inc as a new revelation in the Major Pharmaceutical Preparations sector.
While other companies in the industry have faced significant challenges, Sunshine Biopharma Inc has managed to outperform and exceed expectations. On average, the Major Pharmaceutical Preparations sector has witnessed a contraction of -4.87% in business. However, Sunshine Biopharma Inc has bucked this trend by achieving a revenue gain of 7.136% from the previous financial reporting period.
|
| Sunshine Biopharma Inc
Sunshine Biopharma Inc, a prominent biopharmaceutical company, has recently released its financial results for the time-frame closing on June 30, 2023. The results showcase a balanced book alongside remarkable revenue growth. Moreover, the company's stock has performed well in recent trading sessions, experiencing solid gains and trading above its 52-week low.
Financial Results: Balanced Books and Revenue Growth
During the financial time-frame ending June 30, 2023, Sunshine Biopharma Inc achieved balanced books with earnings per share (EPS) reaching $0.00. This is a significant improvement from the negative EPS of $-0.03 reported a year ago and is on par with the preceding reporting period.
|
| Per Share |
Current |
| Earnings (TTM) |
-12.43 $ |
| Revenues (TTM) |
13.4 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.03 $
|
| Book Value |
8.4 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-12.43 $
|
| Revenues (TTM) |
13.4 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.03 $
|
| Book Value |
8.4 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
